- A Case of Multicentric Castleman's Disease Having Lung Lesion Successfully Treated with Humanized Anti-interleukin-6 Receptor Antibody, Tocilizumab
-
Higuchi T, Nakanishi , Takada K, Matsumoto , Okada M, Horikoshi , Suzuki K
- KMID: 1785918
- J Korean Med Sci.
- 2010 Sep;25(9):1364-1367.
- doi: 10.3346/jkms.2010.25.9.1364
This report presents the case of a patient demonstrating multicentric Castleman's disease (MCD) with a lung lesion that was successfully treated with an anti-interleukin-6 receptor antibody, tocilizumab in combination with... -
- CITED
-
- Close
- SHARE
-
- Close
- Prospective Controlled Protocol for Three Months Steroid Withdrawal with Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients
-
Oh CK, Kim SJ, Kim JH, Lee JH
- KMID: 2157891
- J Korean Med Sci.
- 2012 Apr;27(4):337-342.
- doi: 10.3346/jkms.2012.27.4.337
During the past few years, new immunosuppressants, such as tacrolimus, mycophenolate mofetil (MMF) and basiliximab, have been shown to successfully decrease the incidence of acute rejection, possibly acting as potent... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
-
Kim JM, Lee KW, Song GW, Jung BH, Lee HW, Yi NJ, Kwon CD, Hwang S, Suh KS, Joh JW, Lee SK, Lee SG
- KMID: 2373137
- Clin Mol Hepatol.
- 2016 Sep;22(3):366-371.
- doi: 10.3350/cmh.2016.0022
BACKGROUND/AIMS: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
-
Kim H, Yi NJ, Lee J, Kim J, Moon MR, Jeong J, Lee JM, You TS, Suh SW, Park MS, Choi Y, Hong G, Lee HW, Lee KW, Suh KS
- KMID: 2069766
- Clin Mol Hepatol.
- 2014 Sep;20(3):291-299.
- doi: 10.3350/cmh.2014.20.3.291
BACKGROUND/AIMS: The dose of mycophenolate mofetil (MMF) has been reduced in Asia due to side effects associated with the conventional fixed dose of 2-3 g/day. We aimed to determine the... -
- CITED
-
- Close
- SHARE
-
- Close
- Improved Gastrointestinal Symptoms and Quality of Life after Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients Receiving Tacrolimus
-
Hwang HS, Hyoung BJ, Kim S, Oh HY, Kim YS, Kim JK, Kim YH, Kim YL, Kim CD, Shin GT, Yang CW
- KMID: 1792900
- J Korean Med Sci.
- 2010 Dec;25(12):1759-1765.
- doi: 10.3346/jkms.2010.25.12.1759
It is reported that a conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) relieves gastrointestinal (GI) symptom burden and improves health-related quality of life (HRQoL). However, it is... -
- CITED
-
- Close
- SHARE
-
- Close
- Patients with Persistent New-Onset Diabetes after Transplantation Have Greater Weight Gain after Kidney Transplantation
-
Kim Y, Kim JR, Choi H, Hwang JW, Jang HR, Lee JE, Kim SJ, Kim YG, Kim DJ, Oh HY, Huh W
- KMID: 1777677
- J Korean Med Sci.
- 2013 Oct;28(10):1431-1434.
- doi: 10.3346/jkms.2013.28.10.1431
The purpose of the present study was to evaluate the difference in BMI pattern between patients with persistent new-onset diabetes after transplantation (P-NODAT) and without new-onset diabetes after transplantation (N-NODAT)... -
- CITED
-
- Close
- SHARE
-
- Close
